How expensive can drugs be? The pharmaceutical industry is under increasing pressure to justify the cost of over CHF 100,000 for combined cancer treatment.
Prices of medicines have set it Federal Office for Public Health (BAG). On Wednesday, SRF "Rundschau" broadcasts an example showing how negotiations are taking place. According to documents issued by BAG under public law, it has reached Roche much higher drug prices than originally demanded by the Federal Office.
Pack of the Cancer Drug The smell should become a market entry in 2013 of 1850 francs, according to the federal government. Roche set the price of 3450 francs. In Rundschau, it was claimed that BAG was being put under pressure to determine the price of Roche's cancer drug. Speaker Thomas Christen in the broadcast said the BAG is under pressure from the industry. The Federal Office is in court in 60 cases because no price has been agreed.
However, in the case of Perjeta, BAG objects to the allegations. "The fact is that the price for Perjet is successful," says Christen. Remedy in combination therapy is therefore cheaper than effectively rewarded prices abroad.
The federal council will dare
The Public Eye NGO uses this program as an opportunity to confirm the claim that the confederation must obtain a mandatory license from Perjeta. For a forced license, a pharmaceutical company is forced to make one of its active ingredients manufactured by a third party for substitution in order to reduce the price and ensure the supply of the population.
Angelo Barrile, National Councilor of the SP, made a similar proposal in June. The Federal Council does not want to know about it. "The reduction of healthcare costs through compulsory licenses for new, expensive drugs is possible in the opinion of the Federal Council in the current patent and drug law," he said in his statement. Even the holder of a compulsory self-made drug license "collects all clinical data independently and submits to the regulatory authority, which takes several years and is costly."
Federal government should keep low prices due to threats
The public eye wants to refute this argument with the report of Professor Valérie Junoda of Geneva University. The licensee would therefore be able to request the data required for permission from the Roche patent holder if the patent court found a "public interest" in a forced license. Otherwise, Roche may violate antitrust laws because it uses its dominant position.
Drug experts consider it illusory that the government, through a compulsory license, risks being responsible for the production of the drug. According to the Public Eye campaign, the campaign is primarily concerned that the Federal Council should endanger compulsory licensing in order to limit the pharmaceutical industry's pricing requirements.
Created: 30.01.2019, 20:28 hours